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Abstract Nine different DNA enzymes (DzV3-n, n = 1^9)
targeting the V3 loop region of HIV-1 HXB2 were synthesized.
One of those, DzV3-9, efficiently cleaved the target in the
conserved sequence in the RNA transcript in vitro. DzV3-9 was
stable in the cells and inhibited replication of both NL432 and
SF162 strains in U87 cells expressing CD4 and co-receptors. The
inhibitory effect of DNAzyme on incoming HIV-1 was also
demonstrated with pseudotype virions generated by NL432-based
luciferase reporter genes. Thus, an efficient, stable DNAzyme
against a functionally important region of HIV-1 was identified,
and it may be useful for prevention of HIV-1 infection.
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1. Introduction
DNA in biological systems has long been considered a pas-
sive molecule carrying genetic information. Single-stranded
DNA can also fold into well-de¢ned, sequence-dependent ter-
tiary structures, speci¢cally bind to a variety of target mole-
cules, and exhibit catalytic activities similar to those of ribo-
zymes or protein enzymes [1,2]. Catalytic DNA enzymes
(DNAzymes) have been generated using in vitro selection
methodology. DNAzymes have been shown to target single-
stranded DNA or RNA, and to catalyze chemical reactions
such as phosphoester transfer, phosphoester formation, por-
phyrin metalation, and RNA or DNA cleavage in the pres-
ence of divalent cations [3^6]. Santoro and Joyce generated an
RNA-cleaving DNAzyme which cleaved synthetic oligo-
RNAs corresponding to the start codon regions of HIV-1
gag/pol, env, vpr, tat, and nef [7]. DNAzymes are easier to
prepare and less sensitive to chemical and enzymatic degrada-
tion than ribozymes. However, the application of DNAzymes
in biological contexts, for example as antiviral agents, has not
yet been reported.
Acquired immune de¢ciency syndrome (AIDS) is etiologi-
cally associated with human immunode¢ciency virus (HIV)
infection. Infectious virions of HIV contain two identical cop-
ies of single-stranded RNA. The replication cycle of HIV is
divided into early and late phases. The early phase begins with
attachment of a virion to a cell surface receptor followed by
integration into the host cell genome. The late phase begins
with transcription and processing of viral RNA from the in-
tegrated proviral template and ends with release of progeny
virions from the cell. A recent investigation demonstrated
high plasma HIV RNA levels in infected individuals, and their
prognostic importance [8]. Cleaving the genome RNA of in-
coming virus prior to integration in the early phase as well as
the new transcribed viral RNA in the late phase would e¡ec-
tively interrupt the viral replication cycle. Envelope glycopro-
teins (Env) of HIV-1 play a major role in infection. The V3
loop in Env is formed by a disul¢de bridge between invariant
cysteines at positions 303 and 338 of HIV-1 HXB2 Env pro-
tein (GenBank accession number K03445). Although the V3
loop resides in a variable region, both of its £anking sequen-
ces, including the two invariant cysteine residues, and a cen-
tral tip sequence are highly conserved [9,10]. Previously, we
synthesized phosphorothioate DNA/RNA chimeric ribozymes
against seven di¡erent regions within the V3 loop region of
HXB2. One of them (RzV3-1T), targeted against the con-
served sequences, could speci¢cally suppress the replications
of both T-cell- (X4) and macrophage-tropic (R5) viruses by
reducing envelope gene expression [11].
Our original aim in this study was to clarify if DNAzymes
could inhibit infection by HIV-1 virus. We therefore synthe-
sized RNA-cleaving DNAzymes against nine di¡erent sequen-
ces within the V3 loop in HIV-1 Env. Based on in vitro cleav-
age reactions, the most e⁄cient DNAzyme was selected, and
its intracellular stability was studied using FITC-labeled
DNAzyme. The e¡ect of DNAzymes on infection by incom-
ing HIV-1 virus was also demonstrated.
2. Materials and methods
2.1. Design and synthesis of DNAzymes
Based on Santoro and Joyce’s report, we identi¢ed nine di¡erent
target sequences for RNA-cleaving DNAzymes, each of which in-
cluded an AU in the V3 loop region of HXB2 cDNA between the
two invariant cysteines (7110^7217). The corresponding DNAzymes
(DzV3-n) and their inactive controls (DzV3-nC, T15G) (n = 1^9) were
chemically synthesized (Fig. 1A,B). The £uorescent isothiocyanate
(FITC)-labeled DNAzymes were made by introducing FluoroPrime
at the 5P end. Random oligo-DNA (GTCAGTCAGTCAGTCAGT-
CA) was also synthesized. All the above compounds were synthesized
by Takara Co., Kyoto, Japan.
2.2. Plasmid constructions
A plasmid expressing the env gene of HXB2, pSVIIIenv3-2 [12], was
kindly provided by Dr. J. Sodroski, and was used to generate V3 loop
RNA transcripts for in vitro cleavage assays. For generation of lu-
ciferase reporter gene-containing pseudotype virus, envelope genes of
two T-cell-tropic strains, HXB2 and SF2, and two macrophage-tropic
strains, SF162 and ADA [13], subcloned in pSM vector were used.
pSMHXB2 [14] and pSMADA were kindly provided by Dr. C. Weiss.
pSMSF2 and pSMSF162 were kindly provided by Dr. A. Koito [15].
P. pyralis luciferase expression vector pNL4-3-Luc-E3R3, which con-
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tains a frameshift mutation near the 5P end of env in the NdeI site of
NL43, was kindly provided by Dr. D. Littman [16].
2.3. Cell culture
All cells were cultured at 37‡C in 100% humidi¢ed air containing
5% CO2. A human embryonic kidney cell line, 293T [17], and human
astroglia cell lines expressing CD4 antigen and coreceptor CXCR4
(cell line U87.CD4.CXCR4) or CCR5 (cell line U87.CD4.CCR5)
were kindly provided by Dr. D. Littman [18], and were used as the
target cells for T-cell- and macrophage-tropic viruses, respectively.
The cells were grown in Dulbecco’s modi¢ed Eagle’s medium contain-
ing high glucose (Gibco BRL, Grand Island, NY, USA) and 10% fetal
calf serum (FCS). 300 Wg/ml G418 (geneticin disulfate, Wako Pure
Chem., Osaka, Japan) and 1 Wg/ml puromycin (Sigma, St. Louis, MO,
USA) were added as selection reagents for U87.CD4 with coreceptors
(D-MEM complete medium). The viability of the cells was estimated
using the trypan blue dye exclusion method.
2.4. In vitro cleavage assay
A DNA fragment from the V3 region in pSVIIIenv3-2 was ampli-
¢ed by PCR using oligonucleotide primers as described previously
[10]. The product was subcloned into pT7Blue T-vector, and used
as a template for in vitro RNA transcription with T7 RNA polymer-
ase. The RNA transcript was labeled with [K-32P]UTP during the
transcription and the concentration of the transcript was measured
with a DNA Dipstick kit (Invitrogen, San Diego, CA, USA). The
quanti¢ed transcript was subjected to in vitro cleavage by DNAzymes.
Concentrations of both substrates and DNAzymes ranged from 2 nM
to 20 WM. Autoradiograms of gels were analyzed with a Bio-Image
analyzer (BAS2000) and cleavage products were quantitated using a
densitometer (PDI system, Huntington Station, NY, USA) as de-
scribed previously [19]. Time points were selected to represent the
linear burst and steady-state velocity phases of the catalyst-substrate
pair being tested. Values of apparent Km and Kcat were calculated as
described [11].
2.5. Detection of DNAzymes in the cells
To observe the stability and localization of DNAzymes, 2U104 cells
were seeded in each well of 8-well Lab-Tek chamber slides (Nunc,
Naperville, IL, USA) 1 day before the experiment, and the FITC-
labeled DNAzymes were delivered into U87.CD4.CXCR4 cells using
lipofectamine with Opti-MEM (Gibco BRL) according to the manu-
facturer’s instructions. After 2 h of exposure, the cells were rinsed
twice with D-MEM complete medium and then cultivated in the
same medium. At the indicated times, cells on the slides were sub-
jected to confocal £uorescence microscopy (Axiophot, Zeiss, Jena,
Germany) using a Bio-Rad MRC 600 laser confocal module (Bio-
Rad Lab, Hercules, CA, USA).
2.6. Virus production
An X4 strain, NL432, and two R5 strains, SF162 and ADA, were
used for infection. The target sequences in the V3 loop region of
NL432 and SF162 are identical with that of HXB2, while that of
ADA has a single base substitution near the cleavage site (Table 1).
NL432 was produced by transfection with the proviral DNA clone
pNL432 [20] into 293T cells. SF162 and ADA were propagated in
peripheral blood mononuclear cells activated by 10 Wg/ml phytohe-
magglutinin (Difco Lab., Detroit, MI, USA) as described [15]. The
supernatants were clari¢ed by centrifugation followed by ¢ltration,
and the levels of p24, the core antigen of HIV-1, were determined
by the antigen capture assay (Abbott Laboratories, Abbott Park,
IL, USA). The amounts of virus were expressed as the concentrations
of p24 antigen.
2.7. Infection
U87.CD4.CXCR4 or U87.CD4.CCR5 cells were used as target cells
for X4 or R5 virus infection, respectively. One day before infection,
2U104 target cells were seeded per well in 48-well plates. Two hours
before infection, DNAzymes (8, 16, 32, 64, or 128 pmol) were intro-
duced into the target cells using lipofectamine as described above.
After removal of the extracellular DNAzymes, the cells were gently
washed twice with D-MEM complete medium and then infected with
virus (5 ng or 10 ng of p24 antigen) for 6 h in the presence of 8 Wg/ml
polybrene. The cells were then cultured after they were washed twice
with the same medium. The supernatants were obtained at the indi-
cated times and subjected to the antigen capture assay. The amount of
p24 antigen produced by infected cells not treated with DNAzymes
was used as a control to calculate the percent inhibition by DNA-
zymes.
2.8. Production of luciferase receptor gene-containing pseudotype virus
and luciferase assay
The e¡ects of DNAzymes on the replication of incoming virus were
examined by using pseudotype viruses containing luciferase reporter
gene, pNL43-Luc-E-R-. To con¢rm the speci¢c activity of DNAzyme
on target sequence, the V3 loop corresponding region in pNL43-Luc-
E-R- was deleted by removing the BglII-BglII fragment (7031^7611),
and the resultant plasmid was named pNL4-3-Luc-V33, which was
used as control [11]. These pseudotype viruses were obtained 36 h
after co-transfection of luciferase reporter gene-containing vectors,
and one of the Env-expressing vectors (pSMSF162, pSMADA,
pSMSF2 or pSMHXB2) into 293T cells. Pseudotype virus (10 ng of
p24 antigen/well) was used to infect target cells seeded in 48-well
plates (2U104 cells/well). The infected cells were pretreated with
DNAzymes (64 pmol/well) for 2 h and were harvested at 36 h post
inoculation, and the luciferase activity of each lysate was measured
with a luminometer (Bio Orbit 1251 luminometer, Turku, Finland).
The luciferase activity in cells not treated with DNAzymes was used
as a control to calculate the inhibition by the DNAzymes.
3. Results and discussion
To test the possible application of DNAzymes against in-
fection by incoming HIV-1 virus, we selected target sequences
within the V3 loop region of HIV-1. This region was selected
because HIV infection was reported to be inhibited by ribo-
zymes targeted against the conserved sequences of the V3 loop
region [11,19].
Fig. 1. Structures of DNAzymes and their target sequences. A: A
substrate and a DNAzyme. The £anking sequence of the DNAzyme
(bottom strand) binds to the substrate (top strand) through Wat-
son-Crick pairing. Cleavage occurs at the position indicated by the
arrow. R = A or G; Y = U or C. Sequences of the inactive control
DNAzymes were the same as their corresponding wild-type DNA-
zymes except for the substitution of G13 in the cleavage core by
A13. B: The target sequence in the HXB2 V3 loop region (7094^
7222) is shown. Individual target sequences, expressed by bold capi-
tal characters, are numbered.
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3.1. In vitro cleavage reaction and kinetic analysis
The amounts of cleavage catalyzed by DzV3-n were exam-
ined using the V3 RNA transcript of HXB2 (HXB2-RNA) as
substrate (Fig. 2A). After 2 h of incubation, more than 50% of
the substrate was cleaved by DzV3-4, -7, -8, and -9. However,
little or no cleavage was seen when other DNAzymes were
used. The reason why these four DNAzymes showed higher
cleavage activities than other DNAzymes remains to be eluc-
idated. The tertiary structure of the target RNA probably
a¡ects the results, because all of the target nucleotides were
AU. The target sequences for DzV3-4, -7, and -8 are located
in the variable region, while that for DzV3-9 is located in the
Table 1
Target sequences for DzV3-9 in the V3 loop region of various HIV-
1 strains
Strain Target sequence Co-receptor usage
HXB2a CAAGCACATTGTAAC X4
NL432 ööööööööööööö X4
SF2 Aöööööööööööö X4/R5
SF162 ööööööööööööö R5
ADA öööööööööCö R5
a7206^7220, according to GenBank accession number K03455.
Fig. 2. In vitro cleavage by DNAzymes. A: Cleavage of HXB2-RNA by nine di¡erent DNAzymes. The reactions were performed at 37‡C for
1 h. The molar ratio of DNAzymes to substrates was 100:1. The most slowly migrating band is the intact RNA transcript, and the faster mi-
grating bands are the cleavage products. The numbers of the lanes from 1 to 9P correspond to DNAzymes from DzV3-1 to DzV3-9, respec-
tively and the prime symbol indicates the substitution T15G in the DNAzyme. Lane 10 contained mutated DzV3-9 (G13A), which was used as
inactive control in the following experiment. Lane 11 contained the antisense from DzV3-9 with substrate RNA. Lane 12 contained intact
RNA transcript only. B: Time-dependent cleavage of HXB2-RNA by DzV3-9. Representative experiments with a ratio of 100:1 of DzV3-9 to
substrate are shown. The cleavage products (277 and 137 bases) of HXB2-RNA (414 bases) were as expected. The lane numbers indicate the
following reaction times: 1: 1 min; 2: 5 min; 3: 10 min; 4: 20 min; 5: 40 min.
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conserved region. Therefore, we used DzV3-9 for further in-
vestigations.
According to Santoro and Joyce, the catalytic core tip could
be T, A, or C, with T giving the highest e⁄ciency of cleavage.
In our preliminary experiments, we used G at the core tip as
an inactive control DzV3-nC (T15G), however, modest to
moderate amounts of cleavage products were observed when
it was incubated with HXB2-RNA, and the amounts of cleav-
age products were comparable to those produced by T15A
and T15C. Therefore, we performed in vitro cleavage assays
using DNAzymes with single-base random mutations within
the conserved loop region from 8G to 22A of DzV3-9 (the
numbering is shown in Fig. 1). Several mutated DNAzymes
(G13A, A16G, C17A, A19G, C20T, and G21A) did not show
any cleavage products. We arbitrarily chose G13A as control
DNAzyme (DzV3-9C) in the following experiments. The 414-
base RNA transcript incubated with DzV3-9 was cleaved with
the expected sizes: 277 bases of the 5P fragment and 137 bases
of the 3P fragment. The substrates incubated with DzV3-9C
did not give any detectable cleaved product, indicating that
the catalytic reactions induced by DzV3-9 were speci¢c. A
more detailed series of such in vitro assays could be used to
analyze the structure-function relationships of the DNAzyme.
The catalytic activities of DzV3-9 against HXB2-RNA tran-
scripts were examined and representative data are shown in
Fig. 2B. The Kcat was 2.85U1034 min31, the apparent Km was
9.41U1032 WM, and the Kcat/Km was 3U103 M31 min31. The
catalytic activities and the a⁄nities of DzV3-9 for HXB2-
RNA were reduced to 1/100 and 1/10, respectively, of those
previously found when 15- or 17-nt synthetic RNA substrates
were used [7]. We also compared the activities with those of a
stabilized ribozyme, RzV3-1T, targeting another conserved
region of the V3 loop. The same RNA transcripts were used
as substrates. The Kcat of DzV3-9 was reduced to 1/4 that of
RzV3-1T; however, the Km was also reduced to about 1/10
that of RzV3-1T, indicating that the a⁄nity for the substrate
of DzV3-9 was higher than that of RzV3-1T. Therefore, the
overall kinetic activity, expressed by Kcat/Km was increased by
2-fold compared to that of RzV3-1T.
3.2. The stability of DNAzymes in the cells
Fluorescent signals in the cells were observed after intro-
duction of labeled DNAzymes. Two hours after introduction,
£uorescent signals were detected in both cytoplasm and nu-
cleus in cells treated with DzV3-9 (Fig. 3). Essentially similar
signals were observed up to 24 h. At 48 h, the signals became
weak, but were still detectable in both nucleus and cytoplasm.
In our previous work, the intracellular signal by wild-type
ribozyme (all RNA) faded within 6 h after introduction,
whereas that of stabilized ribozyme, which contained 80%
Fig. 3. The stability of DNAzymes in the cells. Fluorescent-labeled DNAzyme(DzV3-9) was delivered into U87.CD4.CXCR4 cells. The cells
were subjected to confocal £uorescence microscopy at the indicated times (A: 2 h; B: 6 h; C: 9 h; D: 12 h; E: 24 h; F: 48 h).
Fig. 4. E¡ect of DzV3-9 on virus replication. A and B: U87.CD4.CXCR4 cells infected with NL432 virus (A: 5 ng; B: 10 ng of p24 antigen).
The y-axis shows the percent inhibition of p24 antigen production from DzV3-9-treated target cells. The production of p24 in control cells is
(A) 0.1 ng, 8 ng and 180 ng, and (B) 0.2 ng, 15 ng, and 298 ng on days 1, 2 and 3, respectively. The x-axis shows the time of harvest of super-
natants. b : DzV3-9 treatment; a : DzV3-9C treatment. C: U87.CD4.CCR5 cells infected with SF162 strain on day 3. The y-axis shows the per-
cent inhibition of p24 antigen production in DzV3-9-treated target cells. The production of p24 in control cells of 5 ng or 10 ng infection with
SF162 is 160 ng or 258 ng, respectively. The x-axis shows the load of infecting virus. F : DzV3-9 treatment; E : DzV3-9C treatment. The means
and standard deviations from three independent experiments are shown.
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phosphorothioate DNA linkages, was still detectable even
after 24 h. Therefore, the stability of DNAzyme in the cells
was similar to the phosphorothioate DNA/RNA chimeric ri-
bozymes.
3.3. DNAzyme inhibited HIV-1 virus replication
The e¡ect of DzV3-9 on virus replication was determined
and was expressed as percent inhibition. The viability of
DNAzyme-treated U87 cells was greater than 95% before in-
fection, and apparent degenerative changes in the cells were
not seen by microscopic observation after DNAzyme treat-
ment followed by virus infection.
The inhibitory activity of DzV3-9 on NL432 replication was
dose-dependent in U87.CD4.CXCR4 cells, and the optimal
inhibition was seen at 64 pmol/well (data not shown), while
less ribozyme (16 pmol) was required in the similar assay [19].
Therefore, we used 64 pmol of DzV3-9 to treat the target cells
before infection in the following experiments. Two di¡erent
dosages (5 ng or 10 ng of p24 antigen) of virus were used for
infection. Treatment with DzV3-9 suppressed the virus repli-
cation by 77% (5 ng) or 79% (10 ng) on day 2, and 80.7% (5
ng) or 54% (10 ng) on day 3 (Fig. 4A,B). The inhibitory
activity of DzV3-9 on ADA and SF162 virus replication
was also tested in U87.CD4.CCR5 cells. The maximal sup-
pression of SF162 virus replication was observed on day 3,
with 68% and 48% suppression for 5 and 10 ng of infecting
p24 antigen, respectively (Fig. 4C). DzV3-9C also caused
moderate (less than 30%) inhibition of virus replication, how-
ever random oligo-DNA did not cause any inhibition (data
not shown). The catalytic loop in DzV3-9C was inactivated
while the target-binding fragment was intact. Therefore, the
moderate inhibition by DzV3-9C could be explained by its
antisense e¡ect. Moreover, DzV3-9 caused little inhibition of
ADA virus replication (data not shown). The lack of a sup-
pressive e¡ect on the ADA strain might be explained by a
single base substitution near the DNAzyme cleavage site.
Comparable inhibitory activity was achieved at a higher con-
centration of DzV3-9 than that of RzV3-1T. Furthermore, it
is known that many factors are involved in determining the
activity of ribozymes in vivo, such as RNA-binding proteins
and co-localization of substrate and ribozyme [21]. Similar
factors, and also DNA-binding proteins may a¡ect the activ-
ity of DNAzymes in vivo. The identi¢cation of such cellular
factors and their interactions with DNAzymes should be
elucidated.
3.4. DNAzyme inhibited the infection of incoming virus by
single-cycle infection assay
The HIV-1 replication cycle is divided into the early and
late phases. The e¡ect of DNAzymes on replication of incom-
ing virus was elucidated by a sensitive single-cycle infection
system using a luciferase reporter gene. The inhibition by
DzV3-9 was not seen in infection with V3 loop-deleted pseu-
dotype virus, HXB2luc-V33 [11] (data not shown).
U87.CD4.CXCR4 cells were infected with the pseudotype re-
porter viruses coated with Env from HXB2 (HXB2luc-V3)
or SF2 (SF2luc-V3), and U87.CD4.CCR5 cells were infected
with the pseudotype reporter viruses coated with Env from
ADA or SF162 (ADAluc-V3 or SF162luc-V3). The lucifer-
ase activity of pseudotype virus in cells treated with DzV3-9
was markedly lower than that in cells not treated with DNA-
zyme, the inhibition was 74% on HXB2luc-V3, 54% on
SF2luc-V3, 72% on SF162luc-V3, or 74% on ADAluc-
V3 (Fig. 5). These viruses all contained the same reporter
gene, although they were coated with di¡erent viral Env. The
lower inhibition by DzV3-9 against SF2luc-V3 could not be
explained by the di¡erent co-receptor usage because the in-
hibition of HXB2luc-V3 infection, which also uses CXCR4,
was over 70%. It could also not be ascribed to a higher in-
fection e⁄ciency of SF2luc-V3 because luciferase activity in
SF2luc-V3-infected cells was lower than that in the other
pseudotype virus infected cells (see legend to Fig. 5). It should
also be noted that a complete inhibition could not be achieved
by either DNAzyme or ribozyme. The reason for the resist-
ance of some viruses remains to be elucidated.
This is the ¢rst report demonstrating the biological activity
of DNAzyme. In comparison with modi¢ed ribozyme, DNA-
zyme was easier to synthesize, and has similar stability,
though a higher concentration should be administered. The
fate of DNA administered into the body has not been well
characterized. However, it was reported that DNA vaccine
encapsulated in microparticles could enter mucous macro-
phages [22], which are the initial targets for HIV infection.
The primary infection of HIV is known to be mediated by R5
virus via macrophage/dendritic cells. The inhibitory e¡ect
against incoming R5 viruses (ADA, SF162) by DNAzymes
implied that DNAzymes could prevent HIV infection if they
were taken up by the appropriate target cells. As targets for
DzV3-9, 15 nucleotide long sequences identical to that of
HXB2 are present in 70% of HIV-1 clade B group (Los Ala-
mos databases, 1997). If we could include the one single base
mismatch at the distal site, the coverage of DzV3-9 would
increase by 91%.
Taken together, these data suggest that DzV3-9 is a prom-
ising agent, because (1) DzV3-9, directed against the con-
served sequence of the V3 loop of HIV-1 HXB2, cleaved its
target RNA transcript speci¢cally in vitro, (2) DzV3-9 inhib-
ited infection by both X4 and R5 strains, (3) DzV3-9 inhibited
infection by incoming virus.
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